Leu387Trp mutation, aroused in an imatinib-non-responsive CML patient, was selected by imatinib treatment along with other unknown factors responsible for resistance, and then it was overcome by bosutinib. These results will be useful for treating patients with this rare mutation and will advise against automatically considering a new mutation as the cause of TKI resistance.
Crespiatico, I., Bossi, E., Brioschi, F., Piazza, R., Mologni, L., Gambacorti‐passerini, C. (2020). An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization. CLINICAL CASE REPORTS, 8(1), 71-74 [10.1002/ccr3.2531].
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization
Crespiatico, Ilaria
;Bossi, Elisa;Piazza, Rocco;Mologni, Luca;Gambacorti‐Passerini, Carlo
2020
Abstract
Leu387Trp mutation, aroused in an imatinib-non-responsive CML patient, was selected by imatinib treatment along with other unknown factors responsible for resistance, and then it was overcome by bosutinib. These results will be useful for treating patients with this rare mutation and will advise against automatically considering a new mutation as the cause of TKI resistance.
| File | Dimensione | Formato | |
|---|---|---|---|
|
ccr3.2531.pdf
accesso aperto
Tipologia di allegato:
Author’s Accepted Manuscript, AAM (Post-print)
Dimensione
357.99 kB
Formato
Adobe PDF
|
357.99 kB | Adobe PDF | Visualizza/Apri |
|
10281-253982_VoR.pdf
accesso aperto
Tipologia di allegato:
Publisher’s Version (Version of Record, VoR)
Licenza:
Creative Commons
Dimensione
313.99 kB
Formato
Adobe PDF
|
313.99 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
